随着受体学说的深入发展,β阻滞剂(β肾上腺素能受体阻滞剂)治疗指征已迅速扩大到多种脏器系统疾病。本文讨论β阻滞剂在心血管病中临床应用的研究进展。药效学研究进展β阻滞剂的作用机理是竞争性抑制儿茶酚胺结合于β受体部位,阻断儿茶酚胺对易感组织的作用。但各种β阻滞剂之间有药效学差别(附表)。选择性β_1阻滞剂,与β1受体结合能力相对地大于与β_2受体结合能 With the further development of the receptor theory, the indications of β blockers (β adrenergic blockers) have rapidly expanded to a variety of organ system diseases. This article discusses the clinical application of beta blockers in cardiovascular disease research progress. Progress in pharmacodynamics The mechanism of action of beta-blockers is to competitively inhibit the binding of catecholamines to the beta-receptor site and block the effects of catecholamines on susceptible tissues. However, there is a difference between various β-blockers pharmacodynamics (Schedule). Selective β_1 blockers, with β1 receptor binding capacity is relatively greater than β_2 receptor binding energy